Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update
- MeSH Terms
- carcinoma, non-small-cell lung, adenocarcinoma, bronchioloalveolar, lung, ErbB Receptors, HER2, HER-2, HER2-positive, HER2- overexpressing, HER2 gene amplification, Anaplastic Lymphoma Kinase, Receptor Protein-Tyrosine Kinases, Receptor, trkC, Proto-Oncogene Proteins, ROS1, ROS-1, Proto-Oncogene Proteins c-ret, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinase, Genes, erbB-2, Quinazolines, Piperidines, Aminopyridines, Sulfones, Protein Kinase Inhibitors, Carbazoles, Lactams, Macrocyclic, Imidazoles, Pyrimidines, radiotherapy
- Guideline Contact
- Emily Vella; [email protected]
- Keywords
- carcinoma, non-small-cell lung, adenocarcinoma, bronchioloalveolar, lung, radiotherapy
- Date for Review
- In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
- Publication Date
- 2021-02-16
- Date of Last Evidence Search
- 2020-02-04
- Methods Applied
- Systematic review-based, Externally reviewed; Evidence quality assessment
- Publication Scope
- Guidelines
- treatment
- Countries of Application
- Canada
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- ASCO (US)
- PEBC (Program in evidenced-based care)
- Publication Year
- 2021